Holen Sie sich die Stockscreener-App
14.59
1.15%
-0.1681
Schlusskurs vom Vortag:
$14.76
Offen:
$14.68
24-Stunden-Volumen:
16,043
Relative Volume:
0.09
Marktkapitalisierung:
$500.62M
Einnahmen:
$99.53M
Nettoeinkommen (Verlust:
$-21.57M
KGV:
-22.49
EPS:
-0.6488
Netto-Cashflow:
$-9.84M
1W Leistung:
-3.95%
1M Leistung:
-1.62%
6M Leistung:
+3.84%
1J Leistung:
+46.34%
1-Tages-Spanne:
$14.48
$14.77
1-Wochen-Bereich:
$14.47
$15.48
52-Wochen-Spanne:
$9.22
$19.60
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
14.59 | 506.63M | 99.53M | -21.57M | -9.84M | -0.6488 |
ABT
Abbott Laboratories
|
106.34 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.60 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.28 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.48 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace at Wells Fargo conference: IGE push faces FDA test By Investing.com - Investing.com Canada
NPCE: Strong clinical data and regulatory progress position the RNS system for significant growth in epilepsy care - tradingview.com
NeuroPace at Wells Fargo conference: IGE push faces FDA test - Investing.com
NeuroPace (NPCE) CEO uses 1,310 shares to cover taxes - Stock Titan
Over 12% of NeuroPace (NPCE) may be owned by one investor - Stock Titan
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now - Yahoo Finance
Man Group plc Makes New $1.34 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. - MarketBeat
Precision Trading with Neuropace Inc. (NPCE) Risk Zones - Stock Traders Daily
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference - marketscreener.com
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference - Business Wire
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) CEO settles RSU tax bill with 1,126 shares - Stock Titan
NeuroPace (NASDAQ: NPCE) CMO has 358 shares withheld for taxes - Stock Titan
NeuroPace Inc (NPCE) Stock Up 3.8% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Neuropace (NPCE) Results Check: EPS Lands Above Forecast; Share Move: Shares Finish 1.22% Up on the DayGeographic Revenue Trends - dars.gov.et
Deutsche Bank AG Acquires Shares of 938,919 NeuroPace, Inc. $NPCE - MarketBeat
Neuropace (NPCE) Stock: Ends Up by 0.07% at $14.03; Technical Setup: the $13.33 to $14.73 Range Remains in Focus at the CloseMFI Oversold - vinanet.vn
Neuropace (NPCE) Market: Posts a 0.07% Gain to $14.03 in the Current Update; Technical View: the $13.33 to $14.73 Range Remains in Focus in Latest TradingPassive Flow - vinanet.vn
HC Wainwright Has Positive Outlook of NeuroPace Q3 Earnings - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for NeuroPace - MarketBeat
Neuropace (NPCE) Close in Focus: Finishes 1.33% Higher at $14.47 at the Close; Technical Focus: the Price Remains Bounded by the Supplied Support and Resistance on the DayTrend Following Picks - vinanet.vn
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth - Zacks Investment Research
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? - Yahoo Finance
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - Yahoo Finance
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock By Investing.com - Investing.com UK
Cantor Fitzgerald Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $21 - Moomoo
GSA Capital Partners LLP Acquires Shares of 115,535 NeuroPace, Inc. $NPCE - MarketBeat
NeuroPace (NPCE): OrbiMed reports 1.51M-share, 4.4% beneficial stake - Stock Titan
H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
NeuroPace Q2 revenue up 21% to USD 22.8M - Medical Buyer
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeuroPace (NASDAQ:NPCE) Shares Gap DownHere's Why - MarketBeat
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up - Yahoo Finance Singapore
NeuroPace, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
NeuroPace (NPCE) Stock Price Faces Flat Revenue And Lingering Losses - webull.com
Neuropace earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Technical Reactions to NPCE Trends in Macro Strategies - Stock Traders Daily
NeuroPace Inc.: Q2 Earnings Snapshot - aol.com
NeuroPace Q2 Earnings Call Highlights - MarketBeat
NeuroPace Raises FY26 Sales Guidance Above Estimates - scanx.trade
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance - Investing News Network
NPCE: Q2 revenue up 17% to $22.8M; guidance raised; IGE FDA review ongoing with positive outlook - TradingView
NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
NPCE: Revenue up 17% with strong RNS growth; guidance raised; IGE approval path remains active - TradingView
Earnings call transcript: NeuroPace tops Q2 2026 estimates, shares slip after hours - Investing.com
NeuroPace Q2 EPS beats estimates as revenue rises 17% to $22.8 million - scanx.trade
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo! Finance Canada
NeuroPace, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):